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Objective: Randomized controlled trials have shown that growth hormone (GH) therapy has effects
on growth, metabolism, and body composition. GH therapy is prescribed for children with growth
failure and adults with GH deficiency. Carefully conducted observational study of GH treatment
affords the opportunity to assess long-term treatment outcomes and the clinical factors and variables
affecting those outcomes, in patients receiving GH therapy in routine clinical practice.
Design: The NordiNet® International Outcome Study (IOS) and the American Norditropin®
Studies: Web Enabled Research (ANSWER Program ® ) are two complementary,
non-interventional, observational studies that adhere to current guidelines for pharmacoepidemiological data.
Patients: The studies include pediatric and adult patients receiving Norditropin®, as prescribed
by their physicians.
Measurements: The studies gather long-term data on the safety and effectiveness of reallife treatment with the recombinant human GH, Norditropin®. We describe the origins, aims,
objectives, and design methodology of the studies, as well as their governance and validity,
strengths, and limitations.
Conclusion: The NordiNet® IOS and ANSWER Program® studies will provide valid insights
into the effectiveness and safety of GH treatment across a diverse and large patient population
treated in accordance with real-world clinical practice and following the Good Pharmacoepidemiological Practice and STrengthening the Reporting of OBservational studies in Epidemiology
(STROBE) guidelines.
Keywords: growth hormone replacement therapy, treatment outcome, pharmacoepidemiology,
survey

Introduction
Observational studies are valuable for assessing and charting the real-life management
of patients and offer information to complement data from randomized, controlled trials
(RCTs).1,2 RCTs are the recognized principal means of providing high-level evidence
on the efficacy and safety of a therapeutic intervention. However, their results may
have limited applicability or validity in routine clinical practice, where the patients
encountered and the practices adopted in real-world disease management can differ
Clinical Epidemiology 2013:5 119–127
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greatly from those considered and allowed within the protocol
of a controlled trial setting3 (in which, for example, rare and
atypical subgroups are excluded). Non-interventional, observational studies can therefore provide synergistic insights into
the utilization and the effectiveness of treatments and allow
for the evaluation and follow-up of numerous end points
and parameters, including those unrelated to a treatment
intervention, yet important to disease understanding. They
also permit long-term follow-up of large numbers of patients
who are prescribed chronic medication according to standard
clinical practices. Moreover, for all prescribed therapies, the
collection of postmarketing data is critical for the evaluation
and characterization of the real-life effect and risk profile of
treatments and can help in the detection of rare side effects
and treatment interactions.4 Thus, balanced assessments of
therapeutic interventions should draw on a variety of types
of research5 and, within the mix, observational studies can
serve a range of purposes – confirming or refuting previous
findings, discovering new aspects of disease, and exploring
and generating hypotheses for further investigation.3
One therapy area in which observational data in particular can provide valuable evidence and insights is the use of
growth hormone (GH) to manage a host of conditions associated with GH deficiency (GHD) or in which normal growth
is perturbed.6–9 In this therapy area, there is an established
precedent of assessing the response to and safety of long-term
treatment with GH and of supporting and complementing the
clinical trial evidence base through registry tools.10
GH has multiple physiological actions, including the
promotion of linear growth in childhood, and is essential
for the maintenance of normal body composition throughout
life.6,11,12 GH therapy may be used in childhood, to promote
growth in children with GHD and in children with conditions
characterized by insufficient growth, and also has a role in
the management of adults with GHD. It follows that patients
treated with GH, therefore, represent a highly heterogeneous
group in terms of age range and clinical characteristics. GH
treatment has been used in children for more than 50 years
and in adults for over 20 years, and therapy is typically given
long term.11 Many patients receiving GH therapy are enrolled
in observational studies that are designed specifically for the
brand of GH treatment they are receiving.10 These databases
and observational studies have considerably extended the
knowledge of GHD and its treatment, but many issues remain
unresolved.
Norditropin® (somatropin [rDNA origin] injection) (Novo
Nordisk A/S, Bagsværd, Denmark) is a recombinant human
GH used as replacement therapy in patients with GHD or
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as pharmacological treatment for a number of conditions
characterized by insufficient growth.13–16
This paper describes two complementary, large-scale,
non-interventional, observational studies, the NordiNet®
International Outcome Study (IOS) (NCT00960128)17 and
the American Norditropin® Studies: Web Enabled Research
(ANSWER Program®) (NCT00615953),18 that use the same
electronic platform (NordiNet®/NovoNet®) for data management and that have similar aims; namely, to gather long-term
data on the effectiveness and safety of Norditropin® treatment
in the usual clinical setting and to provide insight into the
diseases of the specific endocrine patient populations managed with GH therapy. In this paper we present the origins,
objectives, methodology, and governance of these studies,
followed by a discussion of their validity, strengths, and
limitations, and ongoing and future uses for these two specific
observational studies.

Methods
History
The NordiNet® IOS and ANSWER Program® are complementary international non-interventional registry studies
monitoring the long-term effectiveness and safety of GH
replacement therapy, specifically Norditropin®, in routine
clinical practice. Patients are entered into one or the other
study, depending on location of the treating clinic. The
NordiNet® IOS registry was launched in 2006 and currently
aims to recruit to a planned sample size of 17,000 patients
over a 10-year period. Prior to 2006, the national German
Novo Nordisk non-interventional studies on Norditropin®treated patients, GrowthWin and NordiWin, initiated in 2001
and 2003, respectively, captured data on the long-term safety
and efficacy of Norditropin® in children and adults. The data
from these two studies have been migrated into NordiNet®
IOS.19,20 The ANSWER Program® is an observational, noninterventional study that was launched in 2002 and includes,
in addition, the follow up of some subjects from two 2-year
RCTs assessing Norditropin® in children with GHD or
growth failure. The ANSWER Program® plans to recruit
approximately 18,000 patients and includes both pediatric
and adult patients treated with Norditropin®.

Aims and objectives
The aims and objectives of NordiNet ® IOS and the
ANSWER Program® are to assess the clinical outcomes
of real-life treatment of pediatric and adult patients with
Norditropin®, as prescribed by treating physicians according to standard clinical practice. The studies are gathering
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long-term data on the effectiveness of treatment and follow
short-term and long-term safety in children and adults treated
with Norditropin®. They offer insights into the contemporary
treatment of specific endocrine patient populations, with
respect to demographic, disease, and patient characteristics
such as country, age, sex, pubertal status, and diagnoses. The
long-term and prospective nature of the studies allows for
the analysis of longitudinal data with regard to outcomes and
for the possibility of benchmarking and time-trend assessments to evaluate the quality of treatment, adjusted for
baseline data.
While the NordiNet® IOS and the ANSWER Program®
have separate protocols, these are of similar design, with
similar objectives and methods, and both are web-based
studies sharing the same electronic platform (NordiNet®/
NovoNet®) for data management. This will allow for the
combination of data if required, according to specific questions from researchers, authorities, and other pertinent
stakeholders.
The overall effectiveness objectives of these studies in
children are to investigate the short- and long-term effects
of Norditropin® on linear growth and to identify factors that
modify linear growth in children treated with Norditropin®.
One major goal is to determine the predictive value of baseline parameters such as age, bone age, sex, and diagnostic
indication, and of pretreatment peak GH and insulin-like
growth factor 1 (IGF-I) levels, on treatment outcomes. The
studies are also investigating the effect of treatment in pediatric patients, on body proportion and metabolic parameters.
Both studies have the objective of studying GH-deficient
patients in transition, specifically investigating the effects of
stopping Norditropin® treatment in pediatric GHD patients
who have reached their adult height and the clinical impact
of reinitiating treatment on somatic development in these
patients.
In adults, the studies are investigating the short- and longterm effects of Norditropin® treatment on body composition
and metabolic parameters, and seek to identify factors that
modify those parameters.
In both pediatric and adult patients, the safety of
Norditropin® is being assessed using physician reports
in the databases, of adverse events (AEs), adverse drug
reactions (ADRs), medical events of special interest, and
pregnancies. If an investigator assesses an AE/ADR as
serious (SAE/SADR), he/she is instructed to complete
and “sign” an electronic SAE/SADR form, to send the
information related to this event to the database within
24 hours. The investigator is further instructed to inform the
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local authority about the SAE/SADR, in accordance with
country-specific rules.

Governance of the databases and studies
Data analyses and publication of the combined results from
NordiNet® IOS and the ANSWER Program® are governed by
an international study committee (ISC). The ISC comprises
elected chairpersons drawn from the pediatric and adult
clinical endocrinological specialties, each acting as a national
clinical representative of a country involved in the IOS and
reporting data on at least 100 patients (maximum two representatives per country), and a maximum of five persons from
Novo Nordisk. The ISC meets annually, with the power to call
additional special meetings and to form working groups. The
NordiNet® ISC acts as the custodian of the database and as the
ultimate decision-making body concerning the presentation
and publication of international data from the studies.
Data access, analyses, and reporting are managed under
the guidance of Novo Nordisk, the owners of the data
collected. The studies are conducted in accordance with the
Declaration of Helsinki; for both studies, patients provide
written, informed consent for data collection. All data in
NordiNet® IOS and the NovoNet® ANSWER Program® are
made anonymous. At the individual center level, approval
of the local ethics committee or institutional review board
is a prerequisite for enrollment into NordiNet® IOS and the
NovoNet® ANSWER Program®, in accordance with countryspecific rules.

Validity of NordiNet® IOS and ANSWER Program®
as observational studies
Both NordiNet® IOS and ANSWER Program® are guided by
the Good Pharmacoepidemiological Practice guidelines on
the design and reporting of observational studies, as defined
by the International Society for Pharmacoepidemiology, and
the STrengthening the Reporting of OBservational studies
in Epidemiology (STROBE) guidelines.3,21 Both studies
have a written protocol describing the proposed study tasks,
milestones and timelines, objectives, and rationale, with
full descriptions of the research methods, study conduct,
responsibilities of personnel and facilities, resource commitment, communication and archiving plans for data, and
the processes for AE reporting.

Study designs, data sources, and data flow
There are 20 countries participating in the two studies: 19 in
NordiNet® IOS (Czech Republic, Denmark, Finland, France,
Germany, Hungary, Ireland, Israel, Italy, Lithuania, The
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Netherlands, Norway, Russia, Serbia, Montenegro, Slovenia,
Sweden, Switzerland, UK); and the US in the ANSWER
Program®.
Those eligible for inclusion in the studies are pediatric
and adult patients who are already on Norditropin® treatment
or who are starting on Norditropin® treatment. This includes
patients in the following pediatric diagnosis groups: children
with growth failure or short stature due to GHD (either as an
isolated occurrence or as part of multiple pituitary hormone
deficiency), small for gestational age (SGA), Turner syndrome,
Prader–Willi syndrome, Noonan syndrome (NS), and chronic
renal disease; adult patients with GHD; and GHD patients during transition. This latter group includes GHD patients treated
with Norditropin® during childhood who achieved adult height
and were off treatment for up to a maximum of 2 years before
reassessment of GH status and reconfirmation of GHD. In terms
of clinical diagnoses, the studies collect data based on investigators’ diagnosis and encourage the use of the International
Classification of Diseases 10th Revision (ICD-10) criteria as
the routine tool for categorization of diagnoses.22
The study databases use the same electronic, web-based
platform (NordiNet®/NovoNet®) for electronic data capture in
the study case report forms (CRFs), which provide automatic
data validation at data entry. The data entered into the platforms are specified in the NordiNet®/NovoNet® CRFs, with
certain adjustments and/or additions allowed at the investigator’s discretion. All the physician investigators are trained
in using the web-based application, and the data on the host
server are protected by an individual user ID and password.
The patient ID remains with a patient even if he or she moves
or changes practitioner. This method of assigned patient ID
ensures that patients can be followed long term and through
transition. The electronic signature enables the investigator to
export the data to the central registry database, in accordance
with the NordiNet® IOS and ANSWER Program® protocols;
the data captured therein constitute the NordiNet® IOS and
ANSWER Program® data sets, respectively.
The central registry database is run and supported by
Novo Nordisk. All physicians reporting patient data into the
database in accordance with agreements specified by Novo
Nordisk are considered to be NordiNet® IOS or ANSWER
Program® members and investigators.
All patient data reported into the central database are managed by the Clinical Data Management Department, Novo
Nordisk Inc (for ANSWER Program®) and the Novo Nordisk
Epidemiology Department in Denmark (for NordiNet® IOS).
Data managers follow up on data flow and prepare periodic
reports to ensure the completeness and correctness of data.
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Patient histories and physical examination data are
prospectively or retrospectively entered by the participating
physician investigators, using the web-based CRFs. The
study protocols specify the examination parameters required
at baseline and follow-up visits for both pediatric and adult
patients (Tables 1 and 2). Physician investigators are encouraged to enter data as soon as possible after clinic visits. At the
baseline visit, the following CRF materials are completed:
registration form (for enrollment in the ANSWER Program®),
diagnosis form, background form, history of examinations/
treatments form, baseline form, and menarche form (if
appropriate). Once a pediatric GHD patient has reached adult
height and GH treatment is discontinued, the patient may
continue to be followed up during a transition period for up
to 2 years (the patient will be asked to sign a separate transition informed consent for this). If, at that time, reassessment
of the patient’s GHD diagnostic criteria indicates that the
patient satisfies the diagnostic criteria of adult GHD and the
patient would like to reinitiate GH treatment, the physician
will initiate treatment in the pediatric module but eventually
transfer the patient to an adult endocrinologist using the adult
module, with all information obtained before reinitiation of
GH treatment considered as the baseline information for adult
treatment. At follow-up visits, there is a dedicated follow-up
form; additional forms are used to collect data on AEs, pregnancy, menarche, consent for off-treatment data collection,
diagnosis, change of clinic, and an end-of-registration form
(for subjects leaving the registry).

Study variables
Study data include all relevant demographic and clinical
characteristics of the enrolled adult and pediatric patients,
the dose of Norditropin® and any dose adjustments made
during the course of patient treatment, clinical outcomes, and
quality-of-life measurements. The study protocols provide
clear guidance concerning the data to be captured (Tables 1
and 2); however, data collection is ultimately conducted in
accordance with the routine clinical practice of the center
and investigator.
The effectiveness end points assessed in children include
the effect of Norditropin® on height gain and body weight,
blood biochemistry (including IGF-I, and pituitary and other
hormones, as relevant) and bone age. Uniquely, in NordiNet®
IOS only, there is an option for automatic assessment of
bone age in children, by use of a validated software called
BoneXpert® (Visiana, Holte, Denmark).23
In adult patients, assessed effectiveness end points include
the effect of Norditropin® on body weight and composition,
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Table 1 Pediatric indications: baseline and follow-up visit
examination parameters evaluated across the NordiNet® IOS and
ANSWER® Program studies
Examination
parametera

Baseline Follow- Follow-up
visit
up visits in transition
(only GHD)

Patient ID
X
Date of visit
X
Demographic data/background
information
Date of birth
X
Sex
X
Patient consent
X
Patient consent date
X
Patient consent for offtreatment data collection,
consent date (separate
study form)
Diagnoses
X
Date of diagnoses
X
Gestational age
X
Birth weight
X
Birth length
X
Birth head circumference
X
Pregnancy
X
information (SGA)
Apgar score (SGA)
X
Mother’s measured
X
(or reported) height
Father’s measured
X
(or reported) height
Medical history
X
(TS, NS, GHD)
Treatment history
X
(GHD, oncology
treatment, radiotherapy,
chemotherapy)
Phenotype (TS)
X
History of examinations
X
Auxology
Height
X
Weight
X
Sitting height
X
Arm span
X
Hip circumference
(X)
Triceps skin fold
X
Upper arm
X
circumference
Sexual maturation
Breast (Tanner) female
X
Pubic hair (Tanner)
X
(female and male)
Genitalia (Tanner) (male)
X
Left testis (male)
X
Right testis (male)
X
Menarche (if occurred)
X
Pregnancy
Vital signs
Pulse
X

X

X

Last
visit

X

X

(X)
(X)

(X)
(X)

(X)
(X)

X
X
X
X
(X)
X
X

X
X

X
X
X

(X)
X
(X)
(X)
X
X
X

X
X

(X)
(X)

(X)
(X)

X
X
X
X
X

(X)
(X)
(X)
(X)
X

(X)
(X)
(X)
(X)
X

X

X

X

Table 1 (Continued)
Examination
parametera

Baseline Follow- Follow-up
visit
up visits in transition
(only GHD)

Systolic and diastolic BP
X
Quality of life
X
questionnaire
Imaging
Bone age
X
Cranial imaging (GHD)
X
DEXA
BIA
Cardiac ultrasound/
X
imaging (TS, NS)
Hearing (TS)
GH test (date, type,
X
GH peak)
Biochemistry
IGF-1
X
IGF-1 – SDS
X
IGFBP-3
X
HbA1c
X
Thyroid function
X
(TSH, free T4)
Fasting blood glucose
X
Fasting insulin
X
LDL
X
HDL
X
Triglycerides
X
Total cholesterol
X
FSH, LH (TS)
X
Additional biochemistry (CRD)
Hemoglobin
X
Magnesium
X
Potassium
X
Calcium
X
Phosphate
X
Serum albumin
X
Serum creatinine
X
Serum urea
X
Estimated creatinine
X
clearance
Cystatin C
X
Serum nitrogen
X
Estimated glomerular
X
filtration rate
Alkaline phosphatase
X
(AP)
Fibroblast growth
X
factor 23
Ostase
X
(bone-specific AP)
Serum bicarbonate
X
25-hydroxy-vitamin D
X
Parathyroid hormone
X
Deoxypyridinoline
X
Protein in urine
X
Creatinine in urine
X

X
X

X
X

X
X
X
X
X

X
X

(X)
(X)
(X)
(X)
X

X

X
X
X
X
X

X
X
X
X
X

X
X
X
X
X

X
X
X
X
X
X
X

X
X
X
X
X
X

X
(X)
X
X
X
X
X

X
X
X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X

X
X
X

X
X
X

X

X

X

X

X

X

X
X
X
X
X
X

X
X
X
X
X
X

(Continued)
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Table 1 (Continued)
Examination
parametera

Baseline Follow- Follow-up
visit
up visits in transition
(only GHD)

Dialysis (CRD)
X
GH treatment
Date for start
X
of GH treatment
GH dose
X
GH treatment
reinitiation
Number of missed
injections since last visit
Change of GH
treatment
Concomitant medication X
AEs (details AE study
form)
End of GH treatment
Clinic change
Date of end of
registration in study

X

Last
visit

X

(X)
X

(X)

X

(X)

X

X

(X)

(X)

X
X

X
X

(X)
X
(X)
X
X

quality of life, blood chemistry (including IGF-I, pituitary
hormones and sex hormones routinely, and thyroid and
adrenal hormones if necessary).
All data are collected in accordance with routine medical
practice and country-specific rules, and the CRFs allow for
effectiveness end points to be adapted and edited according
to local situations and practices.

Safety outcomes
The overall safety objectives follow short- and long-term
safety in children and adults treated with Norditropin ®.
At every visit, the investigators ascertain the occurrence of AEs and SAEs, regardless of their relation to
treatment, medical events of special interest (eg, wrong
drug administration), and pregnancies. The investigator
reports information related to SAEs and medical events
of special interest within 24 hours of obtaining knowledge
of the event; pregnancy exposures are reported within
14 calendar days. Nonserious AEs that are not attributed
to treatment are not registered.
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Examination parametera

Baseline
visit

Follow-up
visits

Last
visit

Patient ID
Date of visit
Date of birth
Demographic data/
background information
Sex
Patient consent
Patient consent date
Diagnoses
Date of diagnoses
Medical history (diabetes, tumors,
malignant disease, subarachnoid
hemorrhage, traumatic brain injury)
Radiotherapy
Chemotherapy
Surgery
Physical examination and vital
signs
Height
Weight
Waist circumference
Hip circumference
Upper-arm circumference
Skinfold triceps
Systolic BP
Diastolic BP
Pulse
Smoking
Pituitary imaging
DEXA
Bioimpedance
Biochemistry
GH test (date, type, GH peak)
IGF-I
IGF-I – SDS
IGFBP-3
HbA1c
Fasting blood glucose
Fasting insulin
Thyroid function (TSH, free T4)
Total cholesterol
HDL
LDL
QoL
GH treatment
Date for start of GH treatment
GH dose
Treatment change
Concomitant medication
AE description
(details AE study form)
Pregnancy
Number of missed injections
since last visit
End of GH treatment

X
X
X

X

X

(X)
(X)
(X)

(X)
(X)
(X)

X
X
X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X

X
X

X
X

X
X
X
X
X
X
X
X
X
X
X
X

X
X
X
X
X
X
X
X
X
X
X

X

Notes: The ANSWER® Program does not include BoneXpert® (Visiana, Holte,
Denmark) evaluations. aThe only evaluated parameters are those that are a part of
routine practice, in accordance with local requirements. (X) signifies “if relevant.”
Abbreviations: AE, adverse event; ANSWER, American Norditropin® Studies:
Web Enabled Research; AP, alkaline phosphatase; BIA, bioelectrical impedance
analysis; BP, blood pressure; CRD, chronic renal disease; DEXA, dual-energy
X-ray absorptiometry; Free T4, free thyroxin; FSH, follicle stimulating hormone;
GH, growth hormone; GHD, growth hormone deficiency; HbA1c, hemoglobin A1c;
HDL, high-density lipoprotein; IGF-1, insulin-like growth factor 1; IGFBP-3, insulinlike growth factor binding protein-3; IOS, International Outcome Study; LDL, lowdensity lipoprotein; LH, luteinizing hormone; NS, Noonan syndrome; SDS, standard
deviation score; SGA, small for gestational age; TS, Turner syndrome; TSH, thyroid
stimulating hormone.

124

Table 2 Adult indications: baseline and follow-up visit examination
parameters evaluated across the NordiNet® IOS and ANSWER®
Program studies

X
X
X
X
X
X

X
X

X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X

X
X
X
X

X
X
X

X
X

X
X
X
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(Continued)

Table 2 (Continued)
Examination parametera

Baseline
visit

Follow-up
visits

Clinic change
Date of end of registration in study

Last
visit
X
X

Notes: The ANSWER® Program does not include BoneXpert® (Visiana, Holte,
Denmark) evaluations. aThe only evaluated parameters are those that are a part of
routine practice, in accordance with local requirements. (X) signifies “if relevant.”
Abbreviations: AE, adverse event; ANSWER, American Norditropin® Studies: Web
Enabled Research; BP, blood pressure; DEXA, dual energy X-ray absorptiometry;
GH, growth hormone; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IGF-I,
insulin-like growth factor-I; IGFBP-3, insulin-like growth factor binding protein-3;
IOS, International Outcome Study; LDL, low-density lipoprotein; SDS, standard
deviation score; TSH, thyroid stimulating hormone; QoL, quality of life.

Data analyses and communication
Statistical analyses of study data will be described per analysis and per publication of the study analyses. Novo Nordisk is
committed to communicating, or otherwise making available
for public examination, the results of these studies, regardless
of the outcomes. Study results, which are reviewed regularly
under the governance of the ISC or by investigators and
internal study personnel in the ANSWER Program®, are
presented on a regular basis at major scientific meetings and
published in relevant peer-reviewed journals.

Current data size
As of July 1, 2012, NordiNet® IOS had enrolled 11,370
pediatric patients (GHD: 6716; SGA: 2642; Turner syndrome:
999; idiopathic short stature: 99; NS: 104; Prader–Willi syndrome: 85; and other: 567) and 1837 adult patients (GHD:
1528 and other: 309).
As of September 25, 2012, the NovoNet® ANSWER
Program® had enrolled 13,681 pediatric patients (GHD:
7180; SGA: 1024; Turner syndrome: 718; idiopathic short
stature: 1452, NS: 184; Prader–Willi syndrome: 120; and
other: 2334) and 468 adult patients (GHD: 214 and multiple
pituitary hormone deficiency: 254).

Discussion
The NordiNet® IOS and the NovoNet® ANSWER Program®
studies are similarly designed observational studies that
capture data, via a web-based platform, describing an international, multicenter cohort of patients receiving Norditropin® in routine clinical practice. The primary value of the
NordiNet® IOS and NovoNet® ANSWER Program® observational studies is to provide real-world data on the clinical
effectiveness and safety experience of Norditropin® therapy in
children, adolescents, and adults, with a special focus on the
transition phase. Data from these observational studies will
also help to increase understanding of the patient populations
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and disease areas under study and provide a valid model for
studying treatment effects. The common design allows for the
IOS and ANSWER Program® data to be pooled, providing a
greater number of cases to investigate patient subgroups and
infrequent events, and strengthening the statistical power of
the data. Specific to the NordiNet® IOS study, is the possibility of automatically assessing the bone age in children, and
to both studies, the ongoing collection of normative data on
body composition and IGF-I, in adults.
These international, prospective studies support
research efforts within the field of GH therapy and the
design and potential for collation of study data, and stimulate international cooperation among pediatric and adult
endocrinologists. As described in this paper, the NordiNet®
IOS and NovoNet® ANSWER Program® studies are not
constrained by the strict and highly specific nature of a trial
protocol and, therefore, offer an inclusive picture of the use
and effectiveness of Norditropin® in clinical practice as well
as allowing specific subgroups of patients receiving GH to be
followed and assessed. The protocol of the studies attempts
to capture numerous end points and informative parameters,
including those unrelated to traditional GH treatment end
points. The design of the studies and their CRFs allow flexibility not possible within an RCT, permitting investigators
to add additional data and to suggest additional parameters
and reporting according to their current clinical practices
and observations.
The importance of the databases is reflected in the articles
that have already published data from NordiNet® IOS and
the NovoNet ANSWER Program®.24–26 One of these, from the
NovoNet ANSWER Program®, sought to identify potential
predictors of good response to GH, in children with short
stature of various etiologies;24 a second, using data from
both studies, focused on comparing 2-year treatment outcomes between patients from different diagnostic subgroups
(idiopathic GHD, SGA, idiopathic short stature, or multiple
pituitary hormone deficiency),26 while a third focused exclusively on patients with NS.25 Other publications have reported
on the effects of sex, age, and pubertal status on outcome of
GH treatment in children.27–29
In addition to offering data on long-term treatment effectiveness and a means to easily discover interactions with
other treatments, a unique feature of the NordiNet® IOS and
NovoNet® ANSWER Program® studies is their intentionally
designed capacity to observe and follow pediatric patients
during the transition from childhood to adulthood. It is hoped
that the studies will provide much needed data on the outcomes of children with GHD, treated with GH in childhood
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until adult height is reached, and the effects of treatment
discontinuation and of reinitiation in cases of severe GHD
that persists into adulthood.
Cost-effectiveness data, increasingly required by prescribers and authorities, can be derived from the databases,
which offer current data on GH treatment outcomes across a
heterogeneous patient population. These studies also include
the assessment of bone age performed by the treating clinician, which may be useful in the routine care of pediatric
patients. Collection of data on body composition, using, for
example, bioimpedance analysis, and comparison of this
data with normative data for adult patients with GHD could
also be of great value.
The size of the cohorts studied by NordiNet® IOS and the
NovoNet® ANSWER Program® allows the generation of a
large collective data set that can be interrogated and analyzed
by specific patient subgroups and according to key epidemiological and treatment questions. This means that these
studies will offer insights and data on large patient populations (internationally and nationally), while also having the
depth and flexibility to allow study of particular subsets of
patients within those populations.
There are a number of notable strengths of the NordiNet®
IOS and NovoNet ® ANSWER Program ® observational
studies. The studies collect retrospective data, yet are prospective in design, aiding prompt recognition of effects and
associations, and the patient populations of the studies reflect
and provide a means of surveillance of the diverse patient
groups given Norditropin® in clinical practice, groups which
together constitute a large number of patients exposed to
Norditropin® treatment over a protracted time period. The
validity of these studies is enhanced by their strict adherence
to contemporary guidelines on the principles and conduct
of non-interventional, observational studies, such as those
outlined in STROBE and by the Good Pharmacoepidemiological Practice guidelines.3,21 The software tools used
in these studies provide a secure, sophisticated, and reactive
database. Independent governance of the studies is assured
by an expert and diverse body of counselors, the ISC, which
acts as custodian of the data and advises on all aspects of data
communication, and on publication of the data, regardless of
outcomes, to the medical community.
Potential limitations of the NordiNet® IOS and NovoNet®
ANSWER Program® studies are those common to any observational registry and include the uncontrolled nature of the
study and of data collection, and the potential selection bias
due to enrollment of selected clinics. Potential bias can also be
caused by the systematic error introduced with use of different
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laboratory assays in different clinics. The lack of central laboratory analysis limits the interpretation of relevant blood analyses,
especially IGF-I. There is also a risk for information bias due
to incomplete reporting, poor quality, or erroneous information recording regarding treatment exposure and treatment
outcomes, or due to investigators failing to report confounding
factors, misclassifying a diagnosis, or failing to report data
accurately. The automated data validation system attempts to
mitigate against these aspects of information recording.
The heterogeneous nature of the patient population is
both a limitation and strength of the studies. Both studies permit and support local treatment practices; however,
centers providing data may have very different access to the
use of technologies. Confounders such as these should be
included in the analyses and reported accordingly. There is
also a continuing need to obtain long-term outcome data on
transition patients into adulthood.
In conclusion, the NordiNet ® IOS and NovoNet ®
ANSWER Program® studies will provide valid and important
insights into the effectiveness and safety of GH treatment
across a diverse and large patient population that is treated
in accordance with real-world clinical practice, by following
the Good Pharmacoepidemiological Practice guidelines and
STROBE guidance on the conduct of observational studies.
The studies include an easily performed assessment of bone
age and the possibility of calculating cost-effectiveness and
will offer unique insights into the management of GHD
patients through transition.
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